T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy
ρ and CSA can detect early nerve injury and correlate with electrophysiology in asymptomatic <i>TTRv</i>-carriers. T2<sub>app</sub> increases only in symptomatic ATTRv amyloidosis in whom it correlates with clinical scores and electrophysiology. Our results suggest that T2-relaxometry can provide biomarkers for disease- and therapy-monitoring in the future.
Authors
- Jan Purrucker (ORCID: https://orcid.org/0000-0003-2978-4972)
- Anysia Poncelet
- Martin Bendszus (ORCID: https://orcid.org/0000-0002-9094-6769)
- John M. Hayes (ORCID: https://orcid.org/0000-0002-5677-2216)
- Markus Weiler (ORCID: https://orcid.org/0000-0002-8942-7662)
- Stefan Schönland (ORCID: https://orcid.org/0000-0002-4853-5579)
- Georges Sam (ORCID: https://orcid.org/0000-0003-0255-1722)
- Fabian aus dem Siepen (ORCID: https://orcid.org/0000-0003-4264-1722)
- Ernst Hund (ORCID: https://orcid.org/0000-0002-6158-1190)
- Ute Hegenbart (ORCID: https://orcid.org/0000-0003-1917-6746)
- Sabine Heiland (ORCID: https://orcid.org/0000-0002-2796-3451)
- Jennifer C. Hayes (ORCID: https://orcid.org/0000-0002-6254-9192)
- Kira Göldner
Institutions
- Heidelberg University (DE)
- University of Michigan (US)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- Amyloid
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1080/13506129.2024.2398453
- Citations
- 2
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Alnylam Pharmaceuticals